Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma

• Published in: Clinical chemistry and laboratory medicine Vol. 59; no. 2; pp. 365 - 371
• Main Authors: Tripodi, Armando, Chantarangkul, Veena, Novembrino, Cristina, Scalambrino, Erica, Boscolo-Anzoletti, Massimo, Clerici, Marigrazia, Rossi, Federica, Peyvandi, Flora
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 23.02.2021; Walter De Gruyter & Company
• Subjects: activated partial thromboplastin time; assay standardization; Assaying; Coagulation factors; Dilution; Hemophilia; Inhibitors; Laboratories; Mimicry; Monoclonal antibodies; Plasma; Prophylaxis; Reagents; hemophilia; inhibitors; assay standardization; activated partial thromboplastin time
• ISSN: 1434-6621; 1437-4331
• DOI: 10.1515/cclm-2020-0696

Emicizumab, a monoclonal antibody mimicking the function of factor (F) VIII in the activation of FX by FIXa, is widely used for prophylaxis in hemophilia patients with or without inhibitors to FVIII. Although it is administered at fixed dose, its measurement could be occasionally required. In principle, the emicizumab procoagulant effect could be assessed by the one-stage assay (OSA) currently used to measure FVIII. However, the OSA for FVIII presents with limitations. Furthermore, owing to its potent FVIII-like activity, emicizumab interferes with the measurement of the inhibitor to FVIII, which is often needed in patients on emicizumab. We prepared test samples by spiking a FVIII-deficient plasma with graded amounts of emicizumab. We modified the OSA for FVIII and tested plasma samples for emicizumab concentrations. Furthermore the chromogenic assay (CA) for FVIII with bovine reagents was used to assess for the FVIII inhibitor in patients on emicizumab. Slight modification of the OSA for FVIII (i.e., higher test plasma dilution and longer coagulometer acquisition time) made the regular OSA as a reliable laboratory tool to measure emicizumab concentration as shown by the identity of the regression (observed vs. expected) lines. Furthermore, the inhibitors to FVIII in patients on emicizumab, which were negative when measured by the regular Bethesda assay, were reliably measured by the CA assay employing bovine reagents. The methods currently used to measure FVIII can be easily modified to make the general clinical laboratory able to assist clinicians when dealing with patients on emicizumab.